IN2014KN02410A - - Google Patents

Info

Publication number
IN2014KN02410A
IN2014KN02410A IN2410KON2014A IN2014KN02410A IN 2014KN02410 A IN2014KN02410 A IN 2014KN02410A IN 2410KON2014 A IN2410KON2014 A IN 2410KON2014A IN 2014KN02410 A IN2014KN02410 A IN 2014KN02410A
Authority
IN
India
Prior art keywords
compounds
kinases
study
methods
relates
Prior art date
Application number
Inventor
John Robert Pollard
Philip Michael Reaper
------
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of IN2014KN02410A publication Critical patent/IN2014KN02410A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to compounds useful as inhibitors of ATR protein kinase and combination therapies thereof. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I:wherein the variables are as defined herein.
IN2410KON2014 2012-04-05 2013-04-05 IN2014KN02410A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261620717P 2012-04-05 2012-04-05
PCT/US2013/035466 WO2013152298A1 (en) 2012-04-05 2013-04-05 Compounds useful as inhibitors of atr kinase and combination therapies thereof

Publications (1)

Publication Number Publication Date
IN2014KN02410A true IN2014KN02410A (en) 2015-05-01

Family

ID=48614105

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2410KON2014 IN2014KN02410A (en) 2012-04-05 2013-04-05

Country Status (22)

Country Link
US (4) US20140044802A1 (en)
EP (2) EP2833973B1 (en)
JP (4) JP2015515478A (en)
CN (2) CN104582795B (en)
AU (2) AU2013243291B2 (en)
CA (1) CA2869309C (en)
DK (1) DK2833973T3 (en)
ES (1) ES2654670T3 (en)
HK (1) HK1205028A1 (en)
HR (1) HRP20171915T1 (en)
HU (1) HUE035253T2 (en)
IN (1) IN2014KN02410A (en)
LT (1) LT2833973T (en)
MX (1) MX358818B (en)
NO (1) NO2885404T3 (en)
NZ (3) NZ726671A (en)
PL (1) PL2833973T3 (en)
PT (1) PT2833973T (en)
RS (1) RS56673B1 (en)
SI (1) SI2833973T1 (en)
TW (2) TW201740949A (en)
WO (1) WO2013152298A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2376485B1 (en) 2008-12-19 2017-12-06 Vertex Pharmaceuticals Incorporated Pyrazine derivatives useful as inhibitors of atr kinase
KR20130066633A (en) 2010-05-12 2013-06-20 버텍스 파마슈티칼스 인코포레이티드 Compounds useful as inhibitors of atr kinase
JP2013526540A (en) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Compounds useful as ATR kinase inhibitors
KR102056586B1 (en) 2011-09-30 2019-12-18 버텍스 파마슈티칼스 인코포레이티드 Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors
BR112014007721B1 (en) 2011-09-30 2022-11-01 Vertex Pharmaceuticals Incorporated PROCESSES FOR PREPARING COMPOUNDS USEFUL AS ATR KINASE INHIBITORS
JP2015515478A (en) 2012-04-05 2015-05-28 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Compounds useful as inhibitors of ATR kinases and combinations thereof
US8999632B2 (en) 2012-10-04 2015-04-07 Vertex Pharmaceuticals Incorporated Method for measuring ATR inhibition mediated increases in DNA damage
BR112015012454B1 (en) 2012-12-07 2022-07-05 Vertex Pharmaceuticals Incorporated ATR KINASE INHIBITOR COMPOUNDS, THEIR USE AND PHARMACEUTICAL COMPOSITION COMPRISING THEM
EP2948447B1 (en) 2013-01-23 2016-09-21 Astrazeneca AB Chemical compounds
ES2768678T3 (en) 2013-12-06 2020-06-23 Vertex Pharma 2-Amino-6-fluoro-N- [5-fluoro-pyridin-3-yl] pyrazolo [1,5-a] pyrimidin-3-carboxamide compound useful as an ATR kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
ES2777608T3 (en) 2014-06-05 2020-08-05 Vertex Pharma Radiolabeled derivatives of a 2-amino-6-fluoro-N- [5-fluoro-pyridin-3-yl] -pyrazolo [1,5-a] pyrimidine-3-carboxamide compound useful as ATR kinase inhibitors, the preparation of said compound and different solid forms of it
KR20170016498A (en) 2014-06-17 2017-02-13 버텍스 파마슈티칼스 인코포레이티드 Method for treating cancer using a combination of chk1 and atr inhibitors
TWI656121B (en) 2014-08-04 2019-04-11 德商拜耳製藥公司 2-(morpholin-4-yl)-1,7-naphthyridine
RU2705156C2 (en) * 2014-08-22 2019-11-05 Кловис Онколоджи, Инк. High dosage strength tablets of rucaparib
KR102678021B1 (en) 2015-09-30 2024-06-26 버텍스 파마슈티칼스 인코포레이티드 Pharmaceutical composition for cancer treatment comprising an ATR inhibitor, used in combination with a DNA damaging agent
AU2017205101B2 (en) * 2016-01-08 2023-05-04 Breast Cancer Now Inhibitors of ataxia-telangiectasia mutated and Rad3-related protein kinase (ATR) for use in methods of treating cancer
WO2017123588A1 (en) 2016-01-11 2017-07-20 Merrimack Pharmaceuticals, Inc. Inhibiting ataxia telangiectasia and rad3-related protein (atr)
CN109563144B (en) 2016-06-01 2023-03-28 雅斯娜 Compound (I)
JOP20190197A1 (en) 2017-02-24 2019-08-22 Bayer Pharma AG An inhibitor of atr kinase for use in a method of treating a hyper-proliferative disease
WO2018153972A1 (en) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combination of atr kinase inhibitors and antiandrogens
AR110995A1 (en) 2017-02-24 2019-05-22 Bayer Ag COMBINATION OF QUINASA ATR INHIBITORS WITH RADIO SALT-223
US11439623B2 (en) 2017-04-04 2022-09-13 Case Western Reserve University Method of modulating ribonucleotide reductase
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
CA3071760A1 (en) 2017-08-04 2019-02-07 Bayer Pharma Aktiengesellschaft Combination of atr kinase inhibitors and pd-1/pd-l1 inhibitors
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
US11712440B2 (en) 2017-12-08 2023-08-01 Bayer Aktiengesellschaft Predictive markers for ATR kinase inhibitors
AU2019346012A1 (en) 2018-09-26 2021-04-15 Merck Patent Gmbh Combination of a PD-1 antagonist, an ATR inhibitor and a platinating agent for the treatment of cancer
US20210369705A1 (en) 2018-10-15 2021-12-02 Merck Patent Gmbh Combination therapy utilizing dna alkylating agents and atr inhibitors
WO2020078788A1 (en) 2018-10-16 2020-04-23 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
MX2021005012A (en) 2018-10-30 2021-07-21 Repare Therapeutics Inc Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors.
CA3148767A1 (en) * 2019-07-26 2021-02-04 Health Research, Inc. Treatment of p53-deficient cancers
US12128050B2 (en) 2020-11-10 2024-10-29 New Mexico Tech University Research Park Corporation KP372-1-induced DNA damage as a chemotherapeutic approach to treat cancer
CN117024413B (en) * 2023-10-07 2024-01-09 天津匠新致成科技有限公司 3-aminopyrazine-2-formamide targeted proteolytic chimera, and preparation method, pharmaceutical composition and application thereof

Family Cites Families (218)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309430A (en) 1980-06-27 1982-01-05 Merck & Co., Inc. Pyrazinyl-1,2,4-oxadiazole-5-ones, for treatment of edema, and processes for preparing same
JPS62270623A (en) 1985-12-07 1987-11-25 Daicel Chem Ind Ltd Bis(4-aminophenyl)pyrazine, its production, polyimide and its production
JPS63208520A (en) 1987-02-26 1988-08-30 Terumo Corp Blood platelet agglutination inhibitor containing pyrazine derivative
US5329012A (en) 1987-10-29 1994-07-12 The Research Foundation Of State University Of New York Bis(acyloxmethyl)imidazole compounds
JPH0272372A (en) 1988-09-07 1990-03-12 Konica Corp Electrophotographic sensitive body
JPH0272370A (en) 1988-09-07 1990-03-12 Konica Corp Electrophogoraphic sensitive body
JPH0374370A (en) 1989-08-16 1991-03-28 Terumo Corp Pyrazine derivative and platelet agglutination inhibiting agent or antiinflammatory agent containing the same
JP2597917B2 (en) 1990-04-26 1997-04-09 富士写真フイルム株式会社 Novel dye-forming coupler and silver halide color photographic material using the same
US5572248A (en) 1994-09-19 1996-11-05 Teleport Corporation Teleconferencing method and system for providing face-to-face, non-animated teleconference environment
EP0914318A1 (en) 1996-05-11 1999-05-12 Kings College London Pyrazines
JP4026876B2 (en) 1996-09-05 2007-12-26 日本食品化工株式会社 Luminescent cyclodextrin derivative and method for producing the same
JP2002241379A (en) 1997-03-21 2002-08-28 Dainippon Pharmaceut Co Ltd 3-oxadiazolylquinoxaline derivative
WO1999044609A1 (en) 1998-03-03 1999-09-10 Merck & Co., Inc. FUSED PIPERIDINE SUBSTITUTED ARYLSULFONAMIDES AS β3-AGONISTS
DE19826671A1 (en) 1998-06-16 1999-12-23 Hoechst Schering Agrevo Gmbh 1,3-oxazoline and 1,3-thiazoline derivatives, processes for their preparation and their use as pesticides
AU748816B2 (en) 1998-07-16 2002-06-13 Shionogi & Co., Ltd. Pyrimidine derivatives exhibiting antitumor activity
US7023913B1 (en) 2000-06-14 2006-04-04 Monroe David A Digital security multimedia sensor
DE60028936T2 (en) 1999-02-05 2007-01-11 Debiopharm S.A. CYCLOSPORIN DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
US6738073B2 (en) 1999-05-12 2004-05-18 Imove, Inc. Camera system with both a wide angle view and a high resolution view
EP1377554A1 (en) 1999-06-16 2004-01-07 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
US7015954B1 (en) 1999-08-09 2006-03-21 Fuji Xerox Co., Ltd. Automatic video system using multiple cameras
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
DE60037905T2 (en) 1999-12-17 2009-01-29 Novartis Vaccines and Diagnostics, Inc., Emeryville PYRAZIN-BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3
US6849660B1 (en) 2000-08-01 2005-02-01 Isis Pharmaceuticals, Inc. Antimicrobial biaryl compounds
US6829391B2 (en) 2000-09-08 2004-12-07 Siemens Corporate Research, Inc. Adaptive resolution system and method for providing efficient low bit rate transmission of image data for distributed applications
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
US8085293B2 (en) 2001-03-14 2011-12-27 Koninklijke Philips Electronics N.V. Self adjusting stereo camera system
US6759657B2 (en) 2001-03-27 2004-07-06 Kabushiki Kaisha Toshiba Infrared sensor
JPWO2002080899A1 (en) 2001-03-30 2005-01-06 エーザイ株式会社 Gastrointestinal disease treatment
US6469002B1 (en) 2001-04-19 2002-10-22 Millennium Pharmaceuticals, Inc. Imidazolidine compounds
DE60229059D1 (en) 2001-05-08 2008-11-06 Univ Yale PROTEOMIMETIC COMPOUNDS AND METHOD
SE0102439D0 (en) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102438D0 (en) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
US7145002B2 (en) 2001-09-26 2006-12-05 Merck & Co. Inc. Crystalline forms of carbapenem antibiotics and methods of preparation
GB0124939D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
MXPA04004714A (en) 2001-11-21 2004-08-19 Upjohn Co Substituted aryl 1,4-pyrazine derivatives.
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
SG159380A1 (en) 2002-02-06 2010-03-30 Vertex Pharma Heteroaryl compounds useful as inhibitors of gsk-3
AU2003218738B2 (en) 2002-03-13 2009-01-08 Janssen Pharmaceutica N.V. Sulfonyl-derivatives as novel inhibitors of histone deacetylase
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
US7043079B2 (en) 2002-04-25 2006-05-09 Microsoft Corporation “Don't care” pixel interpolation
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
CA2484209C (en) 2002-05-03 2013-06-11 Exelixis, Inc. Protein kinase modulators and methods of use
US7704995B2 (en) 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
TW200406385A (en) 2002-05-31 2004-05-01 Eisai Co Ltd Pyrazole compound and pharmaceutical composition containing the same
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
WO2004000820A2 (en) 2002-06-21 2003-12-31 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
AU2003282679A1 (en) 2002-10-04 2004-05-04 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
US20040075741A1 (en) 2002-10-17 2004-04-22 Berkey Thomas F. Multiple camera image multiplexer
US7385626B2 (en) 2002-10-21 2008-06-10 Sarnoff Corporation Method and system for performing surveillance
US20040100560A1 (en) 2002-11-22 2004-05-27 Stavely Donald J. Tracking digital zoom in a digital video camera
SE0203752D0 (en) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203754D0 (en) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
US7230098B2 (en) 2003-02-26 2007-06-12 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
US7684624B2 (en) 2003-03-03 2010-03-23 Smart Technologies Ulc System and method for capturing images of a target area on which information is recorded
MXPA05009245A (en) 2003-03-11 2005-10-19 Pfizer Prod Inc Pyrazine compounds as transforming growth factor (tgf) inhibitors.
JP2006520794A (en) 2003-03-21 2006-09-14 スミスクライン ビーチャム コーポレーション Compound
CN101468965A (en) 2003-03-24 2009-07-01 默克公司 Biaryl substituted 6-membered heterocyles as sodium channel blockers
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
GB2400514B (en) 2003-04-11 2006-07-26 Hewlett Packard Development Co Image capture method
US20060252741A1 (en) 2003-05-15 2006-11-09 Colandrea Vincent J 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
WO2004103991A1 (en) 2003-05-20 2004-12-02 'chemical Diversity Research Institute', Ltd. 2-substituted piperidines, focused library and a pharmaceutical compound
US20050123902A1 (en) 2003-05-21 2005-06-09 President And Fellows Of Harvard College Human papillomavirus inhibitors
PE20050206A1 (en) 2003-05-26 2005-03-26 Schering Ag PHARMACEUTICAL COMPOSITION CONTAINING AN INHIBITOR OF HISTONE DEACETILASE
US7986339B2 (en) 2003-06-12 2011-07-26 Redflex Traffic Systems Pty Ltd Automated traffic violation monitoring and reporting system with combined video and still-image data
JP2005020227A (en) 2003-06-25 2005-01-20 Pfu Ltd Image compression device
AR045595A1 (en) 2003-09-04 2005-11-02 Vertex Pharma USEFUL COMPOSITIONS AS INHIBITORS OF KINASE PROTEINS
WO2005034952A2 (en) 2003-10-07 2005-04-21 The Feinstein Institute For Medical Research Isoxazole and isothiazole compounds useful in the treatment of inflammation
US20050116968A1 (en) 2003-12-02 2005-06-02 John Barrus Multi-capability display
WO2005058876A1 (en) 2003-12-16 2005-06-30 Gpc Biotech Ag Pyrazine derivatives as effective compounds against infectious diseases
CN1933838A (en) 2004-02-12 2007-03-21 默克公司 Bipyridyl amides as modulators of metabotropic glutamate receptor-5
US20050276765A1 (en) 2004-06-10 2005-12-15 Paul Nghiem Preventing skin damage
WO2005123672A2 (en) 2004-06-14 2005-12-29 Takeda San Diego, Inc. Kinase inhibitors
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
AU2005269387A1 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
AP2373A (en) 2004-08-26 2012-03-07 Pfizer Enantiomerically pure aminoheteroaryl compounds asprotein kinase inhibitors.
JP2008510792A (en) 2004-08-26 2008-04-10 ファイザー・インク Amino heteroaryl compounds as protein tyrosine kinase inhibitors
US7730406B2 (en) 2004-10-20 2010-06-01 Hewlett-Packard Development Company, L.P. Image processing system and method
EP1807407B1 (en) 2004-10-22 2009-07-29 Janssen Pharmaceutica N.V. Aromatic amides as inhibitors of c-fms kinase
EP1828144A2 (en) 2004-11-12 2007-09-05 OSI Pharmaceuticals, Inc. Integrin antagonists useful as anticancer agents
EP1814882A1 (en) 2004-11-22 2007-08-08 Vertex Pharmaceuticals Incorporated Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
JP4810669B2 (en) 2004-11-25 2011-11-09 コニカミノルタホールディングス株式会社 Organic electroluminescence element, display device and lighting device
GB0428235D0 (en) 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds
CA2590261C (en) 2004-12-27 2011-08-16 Alcon, Inc. Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
GB0500492D0 (en) 2005-01-11 2005-02-16 Cyclacel Ltd Compound
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
MX2007009945A (en) 2005-02-16 2007-09-26 Schering Corp Heterocyclic substituted piperazines with cxcr3 antagonist activity.
EP1874769B1 (en) 2005-04-25 2011-09-14 Merck Patent GmbH Novel aza- heterocycles serving as kinase inhibitors
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
JP2008543754A (en) 2005-06-09 2008-12-04 メルク エンド カムパニー インコーポレーテッド Inhibitor of checkpoint kinase
AU2006275403A1 (en) 2005-08-02 2007-02-08 Lexicon Pharmaceuticals, Inc. 2-aminoaryl pyridines as protein kinases inhibitors
WO2007015632A1 (en) 2005-08-04 2007-02-08 Cgk Co., Ltd. Atm and atr inhibitor
US7394926B2 (en) 2005-09-30 2008-07-01 Mitutoyo Corporation Magnified machine vision user interface
US7806604B2 (en) 2005-10-20 2010-10-05 Honeywell International Inc. Face detection and tracking in a wide field of view
TW200736260A (en) 2005-11-10 2007-10-01 Smithkline Beecham Corp Inhibitors of Akt activity
DE602006011363D1 (en) 2005-12-01 2010-02-04 Hoffmann La Roche Heteroaryl-substituted steroid derivatives as L-CPT1 inhibitors
EP1970377A4 (en) 2005-12-09 2013-02-27 Meiji Seika Kaisha Lincomycin derivative and antibacterial agent containing the same as active ingredient
US20090143410A1 (en) 2005-12-14 2009-06-04 Kanu Maganbhai Patel Isoxazolines for Controlling Invertebrate Pests
CN101340912A (en) 2005-12-22 2009-01-07 爱尔康研究有限公司 (indazol-5-yl) -pyrazines and (1, 3-dihydro-indol-2-one) -pyrazines for the treatment of RHO kinase mediated diseases and conditions
PE20070978A1 (en) 2006-02-14 2007-11-15 Novartis Ag HETEROCICLIC COMPOUNDS AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASES (PI3Ks)
ITMI20060311A1 (en) 2006-02-21 2007-08-22 Btsr Int Spa PERFECT DEVICE FOR WIRE OR FILATIO SUPPLY TO A TEXTILE MACHINE AND METHOD TO IMPLEMENT THIS POWER SUPPLY
GB0603684D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
WO2007096764A2 (en) 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
TW200800203A (en) 2006-03-08 2008-01-01 Astrazeneca Ab New use
JP2009533327A (en) 2006-03-22 2009-09-17 バーテックス ファーマシューティカルズ インコーポレイテッド C-MET Kinase Inhibitors for Treating Proliferative Diseases
US7574131B2 (en) 2006-03-29 2009-08-11 Sunvision Scientific Inc. Object detection system and method
WO2007126964A2 (en) 2006-03-31 2007-11-08 Schering Corporation Kinase inhibitors
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
BRPI0713328A2 (en) 2006-06-22 2012-10-30 Biovitrum Ab pyridine and pyrazine derivatives as mnk kinase inhibitors
EP2038261A2 (en) 2006-06-22 2009-03-25 Mallinckrodt Inc. Pyrazine derivatives with extended conjugation and uses thereof
EP1900727A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Aminopyridine derivatives as kinase inhibitors
KR20090073121A (en) 2006-09-29 2009-07-02 노파르티스 아게 Pyrazolopyrimidines as PI3 'Lipid Kinase Inhibitors
GB0619342D0 (en) 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
MX2009003222A (en) 2006-10-04 2009-04-06 Hoffmann La Roche 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as hdl-cholesterol raising agents.
CN105693730A (en) 2006-10-19 2016-06-22 西格诺药品有限公司 Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
CN101600714B (en) 2006-11-10 2013-08-21 百时美施贵宝公司 Novel pyrindole kinase inhibitors
US20080132698A1 (en) 2006-11-30 2008-06-05 University Of Ottawa Use of N-oxide compounds in coupling reactions
JP2010513232A (en) 2006-12-15 2010-04-30 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 3-H-pyrazolopyridines and their salts, pharmaceutical compositions comprising them, methods for their preparation and their use
EP2125781A2 (en) 2006-12-20 2009-12-02 Amgen Inc. Substituted heterocycles and methods of use
PE20081581A1 (en) 2006-12-21 2008-11-12 Plexxikon Inc PIRROLO [2,3-b] PYRIDINES COMPOUNDS AS KINASE MODULATORS
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
MX2009008531A (en) 2007-02-16 2009-08-26 Amgen Inc Nitrogen-containing heterocyclyl ketones and methods of use.
CN101679266B (en) 2007-03-01 2015-05-06 诺华股份有限公司 PIM kinase inhibitors and methods of their use
JP2008260691A (en) 2007-04-10 2008-10-30 Bayer Cropscience Ag Insecticidal arylisoxazoline derivative
MX2009010071A (en) 2007-04-10 2009-10-16 Bayer Cropscience Ag Insecticidal aryl isoxazoline derivatives.
EP2150255A4 (en) 2007-05-10 2011-10-05 Glaxosmithkline Llc Quinoxaline derivatives as p13 kinase inhibitors
PE20090717A1 (en) 2007-05-18 2009-07-18 Smithkline Beecham Corp QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS
EP2167086A1 (en) * 2007-05-25 2010-03-31 AstraZeneca AB Combination of chk and parp inhibitors for the treatment of cancers
UY31137A1 (en) 2007-06-14 2009-01-05 Smithkline Beecham Corp DERIVATIVES OF QUINAZOLINE AS INHIBITORS OF THE PI3 QUINASA
EP2012409A2 (en) 2007-06-19 2009-01-07 Hitachi, Ltd. Rotating electrical machine
EP2157090A4 (en) 2007-06-21 2011-09-07 Taisho Pharmaceutical Co Ltd PYRAZINAMIDVERBINDUNG
KR20100037047A (en) 2007-06-26 2010-04-08 렉시컨 파마슈티컬스 인코퍼레이티드 Methods of treating serotonin-mediated diseases and disorders
US8461189B2 (en) 2007-06-27 2013-06-11 Merck Sharp & Dohme Corp. Pyridyl derivatives as histone deacetylase inhibitors
GB0713259D0 (en) 2007-07-09 2007-08-15 Astrazeneca Ab Pyrazine derivatives 954
ES2551095T3 (en) 2007-07-19 2015-11-16 Lundbeck, H., A/S 5-membered heterocyclic amides and related compounds
CA2693967A1 (en) 2007-07-19 2009-01-29 Schering Corporation Heterocyclic amide compounds as protein kinase inhibitors
JP4792126B2 (en) 2007-08-01 2011-10-12 ファイザー・インク Pyrazole compounds and their use as Raf inhibitors
WO2009024825A1 (en) 2007-08-21 2009-02-26 Astrazeneca Ab 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors
WO2009037247A1 (en) 2007-09-17 2009-03-26 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
MX2010004491A (en) 2007-10-25 2010-06-21 Astrazeneca Ab Pyridine and pyrazine derivatives - 083.
JP2011511005A (en) 2008-02-04 2011-04-07 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 2-aminopyridine kinase inhibitor
EP2247595B1 (en) 2008-02-25 2011-07-20 F. Hoffmann-La Roche AG Pyrrolopyrazine kinase inhibitors
PL2247592T3 (en) 2008-02-25 2012-01-31 Hoffmann La Roche Pyrrolopyrazine kinase inhibitors
KR20100114095A (en) 2008-02-25 2010-10-22 에프. 호프만-라 로슈 아게 Pyrrolopyrazine kinase inhibitors
CN101952294B (en) 2008-02-25 2014-11-26 霍夫曼-拉罗奇有限公司 Pyrrolopyrazine kinase inhibitors
TW200940537A (en) 2008-02-26 2009-10-01 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
JP2011513332A (en) 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド N- (6-Aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as RAF inhibitors for the treatment of cancer
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
WO2009152087A1 (en) 2008-06-10 2009-12-17 Plexxikon, Inc. Bicyclic heteroaryl compounds and methods for kinase modulation, and indications therefor
GB0814364D0 (en) 2008-08-05 2008-09-10 Eisai London Res Lab Ltd Diazaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase
PT2767537T (en) 2008-08-06 2017-07-17 Medivation Technologies Inc Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
ATE542813T1 (en) 2008-08-06 2012-02-15 Pfizer 6-SUBSTITUTED 2-HETEROCYCLYLAMINOPYRAZINE COMPOUNDS AS CHK-1 INHIBITORS
JP2012506381A (en) 2008-10-21 2012-03-15 バーテックス ファーマシューティカルズ インコーポレイテッド c-MET protein kinase inhibitor
KR20170015566A (en) 2008-11-10 2017-02-08 버텍스 파마슈티칼스 인코포레이티드 Compounds useful as Inhibitors of ATR kinase
JP5930278B2 (en) 2008-11-25 2016-06-08 ユニバーシティー オブ ロチェスター MLK inhibitors and methods of use
CN102232076B (en) 2008-12-05 2014-12-31 霍夫曼-拉罗奇有限公司 Pyrrolopyrazinyl urea kinase inhibitors
EP2376485B1 (en) 2008-12-19 2017-12-06 Vertex Pharmaceuticals Incorporated Pyrazine derivatives useful as inhibitors of atr kinase
CN102325767B (en) 2008-12-22 2014-05-14 阵列生物制药公司 7-phenoxychroman carboxylic acid derivatives
TW201028410A (en) 2008-12-22 2010-08-01 Astrazeneca Ab Chemical compounds 610
MX2011006332A (en) 2008-12-23 2011-06-27 Abbott Lab Anti-viral compounds.
JP5602641B2 (en) 2009-01-30 2014-10-08 富山化学工業株式会社 N-acyl anthranilic acid derivative or salt thereof
JP5353279B2 (en) 2009-02-06 2013-11-27 Ｊｎｃ株式会社 Method for producing coelenteramide or an analog thereof
WO2010093425A1 (en) 2009-02-11 2010-08-19 Sepracor Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
CN101537007A (en) 2009-03-18 2009-09-23 中国医学科学院血液病医院（血液学研究所） Application of N-(thiofuran-2) pyrazolo (1, 5-a) pyridine-3-formanides compounds for preparing antineoplastic
EP2411007A4 (en) 2009-03-27 2012-12-05 Uab Research Foundation MODULATION OF MEDIATION TRANSLATION BY IRES SEQUENCES
AR077468A1 (en) 2009-07-09 2011-08-31 Array Biopharma Inc PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS
JP2012533551A (en) 2009-07-15 2012-12-27 アボット・ラボラトリーズ Pyrrolopyrazine kinase inhibitor
EP2461688B1 (en) 2009-08-07 2016-03-16 Dow AgroSciences LLC Pesticidal compositions
JP2011042639A (en) 2009-08-24 2011-03-03 Kowa Co Biphenylpyrazine compound, and erythropoietin production promoter containing the same as active ingredient
CN101671336B (en) 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 Aromatic heterocyclic pyrimidine derivatives and analogs, preparation methods and uses thereof
DE102009043260A1 (en) 2009-09-28 2011-04-28 Merck Patent Gmbh Pyridinyl-imidazolone derivatives
RU2615130C2 (en) 2009-10-06 2017-04-04 Милленниум Фармасьютикалз, Инк Heterocyclic compounds useful as pdk1 inhibitors
EP2498778A1 (en) * 2009-11-13 2012-09-19 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer
ME02315B (en) 2010-01-18 2016-06-20 Medicines For Malaria Venture Mmv New anti-malarial agents
US8518945B2 (en) 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
CN102933563A (en) 2010-04-08 2013-02-13 Ah美国42有限责任公司 Substituted 3,5-di phenyl-isoxazoline derivatives as insecticides and acaricides
US20130030237A1 (en) 2010-04-15 2013-01-31 Charles Theuer Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
US8916593B2 (en) 2010-05-04 2014-12-23 Pfizer Inc. Alkoxy-substituted 2-aminopyridines as ALK inhibitors
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
AU2011253021A1 (en) 2010-05-12 2012-11-29 Vertex Pharmaceuticals Incorporated 2 -aminopyridine derivatives useful as inhibitors of ATR kinase
EP2568984A1 (en) 2010-05-12 2013-03-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2569286B1 (en) * 2010-05-12 2014-08-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
KR20130066633A (en) 2010-05-12 2013-06-20 버텍스 파마슈티칼스 인코포레이티드 Compounds useful as inhibitors of atr kinase
JP2013526540A (en) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Compounds useful as ATR kinase inhibitors
CA2798970A1 (en) 2010-05-20 2011-11-24 F. Hoffmann-La Roche Ag Pyrrolopyrazine derivatives as syk and jak inhibitors
JP2013529204A (en) 2010-05-20 2013-07-18 エフ．ホフマン−ラ ロシュ アーゲー Pyrrolo [2,3-b] pyrazine-7-carboxamide derivatives and their use as JAK and SYK and inhibitors
MX2013000103A (en) 2010-06-23 2013-06-13 Vertex Pharma Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase.
CN102311396B (en) 2010-07-05 2015-01-07 暨南大学 Pyrazine derivative and preparation method as well as application thereof to pharmacy
EP2407478A1 (en) 2010-07-14 2012-01-18 GENETADI Biotech, S.L. New cyclotetrapeptides with pro-angiogenic properties
JP5782238B2 (en) 2010-07-30 2015-09-24 ルネサスエレクトロニクス株式会社 Voltage detection circuit and control method thereof
KR20140014205A (en) 2011-03-04 2014-02-05 렉시컨 파마슈티컬스 인코퍼레이티드 Mst1 kinase inhibitors and methods of their use
JP5970003B2 (en) 2011-03-04 2016-08-17 ローカス ファーマシューティカルズ インコーポレイテッド Aminopyrazine compounds
JP2014510151A (en) * 2011-04-05 2014-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド Aminopyrazine compounds useful as ATR kinase (TRAKINASE) inhibitors
MX2013013331A (en) 2011-05-17 2014-10-17 Principia Biopharma Inc Azaindole derivatives as tyrosine kinase inhibitors.
EP2723746A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
JP2014522818A (en) 2011-06-22 2014-09-08 バーテックス ファーマシューティカルズ インコーポレイテッド Compounds useful as ATR kinase inhibitors
WO2012178123A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
KR102056586B1 (en) * 2011-09-30 2019-12-18 버텍스 파마슈티칼스 인코포레이티드 Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors
EP2751099B1 (en) 2011-09-30 2017-06-14 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013049720A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013049719A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
BR112014007721B1 (en) 2011-09-30 2022-11-01 Vertex Pharmaceuticals Incorporated PROCESSES FOR PREPARING COMPOUNDS USEFUL AS ATR KINASE INHIBITORS
WO2013071093A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
WO2013071090A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8841449B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2776421A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013071094A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2015515478A (en) 2012-04-05 2015-05-28 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Compounds useful as inhibitors of ATR kinases and combinations thereof
CN103373996A (en) 2012-04-20 2013-10-30 山东亨利医药科技有限责任公司 Bicyclic derivatives serving as CRTH2 receptor antagonist
US8999632B2 (en) 2012-10-04 2015-04-07 Vertex Pharmaceuticals Incorporated Method for measuring ATR inhibition mediated increases in DNA damage
US8912198B2 (en) 2012-10-16 2014-12-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
BR112015012454B1 (en) 2012-12-07 2022-07-05 Vertex Pharmaceuticals Incorporated ATR KINASE INHIBITOR COMPOUNDS, THEIR USE AND PHARMACEUTICAL COMPOSITION COMPRISING THEM
ES2768678T3 (en) 2013-12-06 2020-06-23 Vertex Pharma 2-Amino-6-fluoro-N- [5-fluoro-pyridin-3-yl] pyrazolo [1,5-a] pyrimidin-3-carboxamide compound useful as an ATR kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
ES2777608T3 (en) 2014-06-05 2020-08-05 Vertex Pharma Radiolabeled derivatives of a 2-amino-6-fluoro-N- [5-fluoro-pyridin-3-yl] -pyrazolo [1,5-a] pyrimidine-3-carboxamide compound useful as ATR kinase inhibitors, the preparation of said compound and different solid forms of it
KR20170016498A (en) 2014-06-17 2017-02-13 버텍스 파마슈티칼스 인코포레이티드 Method for treating cancer using a combination of chk1 and atr inhibitors
KR102678021B1 (en) 2015-09-30 2024-06-26 버텍스 파마슈티칼스 인코포레이티드 Pharmaceutical composition for cancer treatment comprising an ATR inhibitor, used in combination with a DNA damaging agent

Also Published As

Publication number Publication date
RS56673B1 (en) 2018-03-30
JP6770490B2 (en) 2020-10-14
PL2833973T3 (en) 2018-02-28
US20160030424A1 (en) 2016-02-04
HRP20171915T1 (en) 2018-02-09
NZ726671A (en) 2018-04-27
MX358818B (en) 2018-09-05
MX2014011908A (en) 2014-11-25
US20200222392A1 (en) 2020-07-16
EP3311816A1 (en) 2018-04-25
US20140044802A1 (en) 2014-02-13
CN104582795B (en) 2018-04-20
HK1206298A1 (en) 2016-01-08
PT2833973T (en) 2017-12-21
JP2020196748A (en) 2020-12-10
TWI644672B (en) 2018-12-21
WO2013152298A1 (en) 2013-10-10
NZ720511A (en) 2016-12-23
SI2833973T1 (en) 2018-04-30
EP2833973A1 (en) 2015-02-11
CN108478577A (en) 2018-09-04
HUE035253T2 (en) 2018-05-02
AU2013243291B2 (en) 2018-02-01
HK1205028A1 (en) 2015-12-11
US20220233521A1 (en) 2022-07-28
AU2013243291A1 (en) 2014-10-23
JP2015515478A (en) 2015-05-28
ES2654670T3 (en) 2018-02-14
CA2869309A1 (en) 2013-10-10
AU2018200562A1 (en) 2018-02-15
DK2833973T3 (en) 2018-01-02
TW201406375A (en) 2014-02-16
LT2833973T (en) 2018-02-12
JP2017186385A (en) 2017-10-12
TW201740949A (en) 2017-12-01
NO2885404T3 (en) 2018-09-22
EP2833973B1 (en) 2017-09-13
CN104582795A (en) 2015-04-29
NZ700580A (en) 2016-07-29
US10478430B2 (en) 2019-11-19
US11110086B2 (en) 2021-09-07
JP2018150379A (en) 2018-09-27
CA2869309C (en) 2021-02-09

Similar Documents

Publication Publication Date Title
IN2014KN02410A (en)
MX2015007101A (en) Compounds useful as inhibitors of atr kinase.
MX2012013081A (en) Compounds useful as inhibitors of atr kinase.
IN2014KN00943A (en)
MX2012013082A (en) 2 -aminopyridine derivatives useful as inhibitors of atr kinase.
WO2011143425A3 (en) Compounds useful as inhibitors of atr kinase
WO2011143423A3 (en) Compounds useful as inhibitors of atr kinase
WO2014143242A8 (en) Compounds useful as inhibitors of atr kinase
MX2011006503A (en) Pyrazine derivatives useful as inhibitors of atr kinase.
HK1223096A1 (en) Imidazopyridazines useful as inhibitors of the par-2 signaling pathway
MX2011004953A (en) Compounds useful as inhibitors of atr kinase.
MX353461B (en) Processes for making compounds useful as inhibitors of atr kinase.
EA201500182A1 (en) 4-METHYL-2,3,5,9,9b-PENTAASACYCLOPENT [a] NAFTAIL
EA024842B9 (en) Compounds as modulators of pi3k protein kinase
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
MX336051B (en) Diarylacetylene hydrazide containing tyrosine kinase inhibitors.
WO2014194245A3 (en) Cdk8 inhibitors and uses thereof
MX348451B (en) Derivatives of n- [(1h-pyrazol-1-yl) aryl] - 1h - indole or 1h - indazole - 3 - carboxamide, their preparation and their use as p2y12 antagonists.
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
UA110793C2 (en) Pyrazolyl hinoksalinovi kinase inhibitors
UA110978C2 (en) Azetidinylphenyl, pyridyl or pyrazinylcarboxamide derivatives as JAK inhibitors
NZ743260A (en) Bipiperidine-2-one compounds for the preparation of pyrimidinyl tyrosine kinase inhibitors